This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents (BESS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2014 by Seung-Jea Tahk, Ajou University School of Medicine.
Recruitment status was:  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Seung-Jea Tahk, Ajou University School of Medicine
ClinicalTrials.gov Identifier:
NCT01268371
First received: December 29, 2010
Last updated: February 11, 2014
Last verified: February 2014
December 29, 2010
February 11, 2014
December 2010
July 2015   (Final data collection date for primary outcome measure)
The Number of Participants with Majour Adverse Cardiac Events (composite of death, myocardial infarction, target vessel revascularization and stent thrombosis [ Time Frame: 1 year after index procedure ]
The composite of death, myocardial infarction, target vessel revascularization and stent thrombosis [ Time Frame: 1 year after index procedure ]
Complete list of historical versions of study NCT01268371 on ClinicalTrials.gov Archive Site
  • The number of participants with majour adverse cardiac events (composite of death, myocardial infarction, target vessel revascularization and stent thrombosis [ Time Frame: 2 years after index procedure ]
  • Death (all-cause and cardiac) [ Time Frame: 1 to 2 years after index procedure ]
  • Myocardial infarction (Q wave and non-Q wave) [ Time Frame: 1 to 2 years after index procedure ]
  • Target vessel revascularization (ischemia- and clinically-driven) [ Time Frame: 1 to 2 years after index procedure ]
  • Target lesion revascularization (ischemia- and clinically-driven) [ Time Frame: 1 to 2 years after index procedure ]
  • Stent thrombosis [ Time Frame: 1 to 2 years after index procedure ]
  • In-stent and in-segment late loss at 1 year angiographic follow-up [ Time Frame: 1 year after index procedure ]
  • In-stent and in-segment restenosis at 1 year angiographic follow-up [ Time Frame: 1 year after index procedure ]
  • Incidence and angiographic pattern of restenosis at 1 year angiographic follow-up [ Time Frame: 1 year after index procedure ]
  • The incidence of Procedural success [ Time Frame: index procedure (day 0) ]
  • The number of participants with death and myocardial infarction [ Time Frame: 1 to 2 years after index procedure ]
  • The composite of death, myocardial infarction, target vessel revascularization and stent thrombosis [ Time Frame: 2 years after index procedure ]
  • Death (all-cause and cardiac) [ Time Frame: 1 to 2 years after index procedure ]
  • Myocardial infarction (Q wave and non-Q wave) [ Time Frame: 1 to 2 years after index procedure ]
  • Target vessel revascularization (ischemia- and clinically-driven) [ Time Frame: 1 to 2 years after index procedure ]
  • Target lesion revascularization (ischemia- and clinically-driven) [ Time Frame: 1 to 2 years after index procedure ]
  • Stent thrombosis [ Time Frame: 1 to 2 years after index procedure ]
  • In-stent and in-segment late loss at 1 year angiographic follow-up [ Time Frame: 1 year after index procedure ]
  • In-stent and in-segment restenosis at 1 year angiographic follow-up [ Time Frame: 1 year after index procedure ]
  • Incidence and angiographic pattern of restenosis at 1 year angiographic follow-up [ Time Frame: 1 year after index procedure ]
  • Procedural success [ Time Frame: index procedure (day 0) ]
  • The composite of death and myocardial infarction [ Time Frame: 1 to 2 years after index procedure ]
Not Provided
Not Provided
 
Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents
Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents
To compare the safety and efficacy of coronary stenting with everolimus-eluting stent (Promus Element®) and biolimus-eluting stent with biodegradable polymer (Nobori®)
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Coronary Artery Disease
  • Device: Promus Element, Boston Scientific Corporation
    Everolimus-eluting stent
    Other Name: Everolimus-eluting stent
  • Device: Nobori, Terumo Corporation (Japan)
    Biolimus-eluting stent with biodegradable polymer
    Other Name: Biolimus-eluting stent with biodegradable polymer
  • Active Comparator: Promus Element
    Everolimus-eluting stent
    Intervention: Device: Promus Element, Boston Scientific Corporation
  • Active Comparator: Nobori
    Biolimus-eluting stent with biodegradable polymer
    Intervention: Device: Nobori, Terumo Corporation (Japan)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
1462
July 2015
July 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Significant coronary artery stenosis (> 50% by visual estimate)
  • Stable angina, unstable angina, Non-ST elevation myocardial infarction (NSTEMI) and documented silent ischemia
  • Patients eligible for intracoronary stenting
  • age ≥ 20 years old

Exclusion Criteria:

  • ST segment elevation myocardial infarction (within 24 hours)
  • Low ejection fraction (< 25%)
  • Cardiogenic shock
  • History of bleeding diathesis or known coagulopathy
  • Limited life-expectancy (less than 1 year) due to combined serious disease
  • Contraindication to heparin, sirolimus, everolimus and biolimus
  • Contraindication to aspirin and clopidogrel
  • Pregnancy
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01268371
BESS
Yes
Not Provided
Not Provided
Seung-Jea Tahk, Ajou University School of Medicine
Ajou University School of Medicine
Not Provided
Principal Investigator: Seung-Jea Tahk, MD, PhD Department of Cardiology, Ajou University School of Medicine
Ajou University School of Medicine
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP